哌拉西林他唑巴坦联合左氧氟沙星治疗重症肺炎的评价.pdfVIP

中国城乡企业卫生2012 年6 月第3 期（总第149 期） 【临床医学】 哌拉西林/ 他唑巴坦联合左氧氟沙星治疗重症肺炎的评价 赵莲花，张静 摘要：目的评价哌拉西林/ 他唑巴坦联合左氧氟沙星对老年重症社区获得性肺炎的治疗效果。方法回顾性分析哌拉 西林/ 他唑巴坦联合左氧氟沙星治疗156 例老年重症社区获得性肺炎的临床疗效。结果平均疗程11.5d，细菌清除率 达84.4%，临床有效率为92.9%，不良反应发生率7.0%，不良反应轻微，主要包括:胃肠道症状、皮疹、白细胞减少及肝功 能异常等，均经停药或对症处理后缓解。结论 哌拉西林/ 他唑巴坦联合左氧氟沙星治疗老年重症社区获得性肺炎临 床效果肯定，不良反应小，可作为治疗老年重症社区获得性肺炎的经验性用药。 关键词：哌拉西林/ 他唑巴坦；左氧氟沙星；重症肺炎；治疗 Efficacy of piperacillin/tazobactam and levofloxacin for treatment of severe community acquired pneumonia Zhao Lian-hua Department of Internal Medicine , The TEDA Hospital of Tian- jin ,Tian- jin 300457, China Abstract: Objective To evaluate the efficacy and safety of piperacilli/tazobactam and levofloxacin for the elderly severe community acquired pneumonia (SCAP). Methods The clinical efficacy data of 156 SCAP patients treated with piperacillin/tazobactam combined with levofloxacin were retrospectively analyzed. Results The total effective rate was 92.9% and the average course of treatment was 11.5days Bacterial clearance rate was 84.4%. The side －effect rate was 7.0%, mostly were gastrointestinal upset, skin rash, leucopenia and hypohepatia. They were light and could be released after drug discontinuance or treating symptom. Conclusion Piperacillin/tazobactam combined with levofloxacin is effective and safe for SCAP and can be used as experiential antibiotics. Key words: Piperacilli/tazobactam; Severe pneumonia; Levofloxacin; Treatment 社区获得性肺炎是指在医院外罹患的感染性肺 岁，平均年龄72 岁。原有慢性阻塞性肺病29 例，合 炎，它有明确的潜伏期，也可在入院后发病，是感染性 并呼吸衰竭者51 例，感染性休克者7 例，多器官功